Thus, research into immunotherapy targeting TLR4/MD-2 complex-mediated MyD88/NF-κB and Akt pathways of EOC cells will probably become focused on an approach to combination immunotherapy that simultaneously intensify anti-tumor immune responses while reversing tumor immune suppression. This evidence concerns the gene TLR4 and neoplasm.